NeuroSense terminates prior ‘at-the-market’ equity offering program

NeuroSense announced it has terminated its previously established “at-the-market” equity offering program. The termination will take effect at the close of business on October 4th, 2023, following the 3-day termination process of the ATM offering. “Having completed enrollment in our Phase 2b ALS trial in the second quarter, we continue to dose and monitor patients for the 6-month double blind portion of the study. We also expect to enroll our first patient in our new Phase 2 Alzheimer’s disease study in the coming weeks. With clarity on our R&D and operating expenses, we are confident that our company is fully funded into the second quarter of 2024,” stated NeuroSense Founder and CEO, Alon Ben-Noon. “With our extensive use of biomarkers in the Phase 2b study, we are optimistic about PrimeC’s mechanism of action and its corresponding clinical results anticipated in Q4 2023.”